Boulding Mark Elliott sold $432K of PTCT
Boulding Mark Elliott (EXEC. VP AND CLO) sold 5,079 shares of PTC THERAPEUTICS, INC. (PTCT) at an average of $85.08 ($83.10–$86.38, $0.43M total) across 8 trades on 2026-07-06 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest concrete fact is the reported open-market sale amount and share count under a pre-arranged 10b5-1 plan; it does not include any new operational, clinical, or financial guidance.
Market read
Traders may note the insider sale for sentiment, but there is no fundamental catalyst in the filing.
What to watch
The article does not state whether the sale was part of a broader pattern, nor does it provide option exercises, purchases, or net insider activity beyond this single transaction.
Background
The article is a SEC Form 4 insider transaction disclosure for PTC Therapeutics, reported by an executive (exec VP and CLO).
Ticker impact
PTC Therapeutics Form 4 shows exec VP and CLO Mark Elliott sold 5,079 shares in an open-market sale totaling about $432K.
Likely limited near-term impact; any effect would be sentiment-driven rather than fundamental.
The filing is a routine Form 4 disclosure, specifies a pre-arranged 10b5-1 plan, and provides no new company fundamentals, guidance, or regulatory/operational event.
Market effects
No direct sector read-through; this is company-specific insider transaction data.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can still be interpreted as risk management or diversification, which some traders may front-run with caution.
Key entities
- issuerPTC THERAPEUTICS, INC.
Company whose Form 4 insider sale is disclosed.
- insiderBoulding Mark Elliott
Exec VP and CLO who sold shares under a 10b5-1 plan.
